Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 7 от 154

Набира участници Фаза 1

Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers

High Cholesterol

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects

Начало: 12.03.2026 Край: 01.07.2027 Възраст: 18–65 г. Лечение

Australia Ikaria Bioscience Pty Ltd NCT07347678

Набира участници Фаза 2

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

Начало: 11.03.2026 Край: 30.07.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +2 Hoffmann-La Roche NCT07287150

Набира участници Фаза 1

A Dose-Escalation Study of RO7875913 in Healthy Participants

Healthy Volunteers

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.

Начало: 11.03.2026 Край: 31.12.2026 Възраст: 18–65 г. Лечение

New Zealand Genentech, Inc. NCT07342114

Набира участници Фаза 2

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Idiopathic Pulmonary Fibrosis (IPF)

This study will evaluate the impact Nintedanib Solution for Inhalation (AP02) has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) as well as assess its safety and tolerability. Adults 40 years of age or older with IPF who meet the inclusion and exclusion criteria can participate in this study if they are not currently on treatment for IPF, and if treated with oral nintedanib or pirfenidone, have stopped the medication for at least 3 months. Researchers will compare two different doses of AP02 to a placebo (a look-alike substance that contains no drug) to see if AP02 works to treat IPF. Participants are put into 1 of 3 groups randomly, which means by chance and will take AP02 or a placebo two times every day for 12 weeks by using a nebulizer, which is a device that provides medicine to the lungs via inhalation. Participants will visit the office 6 times and receive 1 phone call over a 16-week period. At site visits doctors regularly perform breathing tests that measure how well the lungs are working, give the patient questionnaires and will check the participants' health.

Начало: 10.03.2026 Край: 01.06.2027 Възраст: от 40 г. Лечение

Australia, Canada Avalyn Pharma Inc. NCT07194382

Набира участници Фаза 1

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

Pneumonia, Bacterial

This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.

Начало: 10.03.2026 Край: 24.12.2026 Възраст: 50–64 г. Превенция

Australia GlaxoSmithKline NCT07428759

Набира участници Фаза 4

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia Lymphoma, Small Lymphocytic

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Начало: 09.03.2026 Край: 01.12.2032 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +12 Eli Lilly and Company NCT07218341

Набира участници Фаза 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy Secondary to Age-related Macular Degeneration

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Начало: 09.03.2026 Край: 22.08.2029 Възраст: от 50 г. Лечение

Australia, United States Novartis Pharmaceuticals NCT07441642

Набира участници Фаза 1

A Trial of SHR-2173 in Healthy Volunteers

Immunology

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants

Начало: 06.03.2026 Край: 30.08.2026 Възраст: 18–45 г. Лечение

Australia Atridia Pty Ltd. NCT07390747

Набира участници Фаза 2

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

Hepatitis B, Chronic

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.

Начало: 06.03.2026 Край: 31.12.2028 Възраст: 18–65 г. Лечение

Australia, China, New Zealand +3 AusperBio Therapeutics Inc. NCT07370207

Набира участници Фаза 1

A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).

Rheumatoid Arthritis (RA)

This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).

Начало: 06.03.2026 Край: 01.08.2027 Възраст: 18–75 г. Лечение

Australia Kali Therapeutics, Inc. NCT07234773

Набира участници Фаза 1/2

A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

Castration-resistant Prostate Cancer

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).

Начало: 05.03.2026 Край: 30.03.2029 Възраст: от 18 г. Лечение

Australia Radiopharm Theranostics, Ltd NCT07259213

Набира участници Фаза 3

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

CRC (Colorectal Cancer)

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Начало: 05.03.2026 Край: 28.09.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +16 Incyte Corporation NCT07284849

Набира участници Фаза 1

A Study of MK-7240 in Healthy Participants (MK-7240-009)

Healthy

The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.

Начало: 05.03.2026 Край: 03.09.2026 Възраст: 18–55 г. Фундаментална наука

Australia Merck Sharp & Dohme LLC NCT07405177

Набира участници Фаза 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Non-alcoholic Fatty Liver Disease

This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.

Начало: 05.03.2026 Край: 17.08.2026 Възраст: 18–55 г. Лечение

New Zealand GlaxoSmithKline NCT07335198

Набира участници

An Evaluation of the Safety and Tolerability of Ocular Lubricants

Dry Eye Disease

The purpose of this study is to evaluate the safety and tolerability of two new artificial tear formulations in subjects with moderate dry eye disease.

Начало: 04.03.2026 Край: 01.08.2026 Възраст: от 18 г. Лечение

Australia Alcon Research NCT07238699

Набира участници Фаза 3

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Lung Cancer Lung Metastases

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.

Начало: 01.03.2026 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia, United States Vergent Bioscience, Inc. NCT07499674

Набира участници Фаза 1

Assess the Safety and Tolerability of SNS851 in Healthy Participants

Metabolic Disease

This is a Phase I, randomized, double-blind study designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.

Начало: 01.03.2026 Край: 01.10.2026 Възраст: 18–55 г. Лечение

Australia Oneness Biotech Co., Ltd. NCT07417124

Набира участници

CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research

Clonal Hematopoiesis CCUS Clonal Cytopenia of Undetermined Significance Hematologic Disease and Disorders

People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study. Individuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH. Researchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes. The information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia. Participants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.

Начало: 01.03.2026 Край: 01.11.2033 Възраст: от 55 г.

Australia Clinical Hub for Interventional Research (CHOIR) NCT07313059

Набира участници

Investigating the Acceptance and Performance of Low Energy Audio Streaming in Nucleus 8 and Kanso 3 Sound Processors by Experienced Cochlear Implant Users

Cochlear Implant Users

This study aims to investigate acceptance and performance of the Bluetooth Low Energy Audio-enabled (LE Audio) firmware in the Nucleus 8 Processing Unit, Kanso 3 Nexa Sound Processor, and the Kanso 3 Sound Processor. The investigation includes actual use (take home) of LE Audio firmware releases and the new GN ReSound LE Audio wireless accessories, including the Multi-Mic+, for use in the real-world. Using the final versions of firmware, speech perception performance in noise will be investigated using the Nucleus 8 and Kanso 3 Sound Processors streaming via a Multi-Mic+.

Начало: 01.03.2026 Край: 01.10.2027 Възраст: от 18 г. Друго

Australia Cochlear NCT07262827

Набира участници Фаза 1/2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Lymphoma Waldenström Macroglobulinemia (WM) DLBCL - Diffuse Large B Cell Lymphoma PMBCL +4

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma

Начало: 01.03.2026 Край: 01.04.2030 Възраст: от 18 г. Лечение

Australia ModeX Therapeutics, An OPKO Health Company NCT07249905

1 … 5 6 7 8 9 … 154